Prevalence of metabolic syndrome and related factors in a large sample of antipsychotic naïve patients with first-episode psychosis: Baseline results from the PAFIP cohort

Garrido-Torres, Nathalia; Ruíz-Veguilla, Miguel; Alameda, Luis; Canal‐Rivero, Manuel; Ruíz, M. Juncal; Gómez-Revuelta, Marcos; Ayesa-Arriola, Rosa; Rubio-García, Ana; Crespo‐Facorro, Benedicto; Vázquez‐Bourgon, Javier

doi:10.1016/j.schres.2022.07.007

Cited by 12 publications

(15 citation statements)

References 73 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Patients with MetS were significantly older and sick longer than those without MetS. Although drug-naive people with schizophrenia are more likely to have MetS than healthy individuals [ 7 , 8 ], and therefore the schizophrenic disease process itself may influence the prevalence of MetS, no conclusions should be drawn from this in our case. Age itself is an important factor [ 30 , 31 ], and probably disease duration also correlates with the duration of exposure to (atypical) antipsychotics.…”

Section: Discussionmentioning

confidence: 79%

“…Antipsychotics are undoubtedly the most commonly used to treat the symptoms of an exacerbation of schizophrenia and to prevent a new outbreak of the disease. Although the prevalence of (components of) MetS is also increased in antipsychotic-naive patients with schizophrenia [ 7 , 8 ], the prevalence is higher in people with schizophrenia treated with antipsychotics [ 9 ]. Regarding the former, there is evidence that schizophrenia and MetS share some of the same risk factors and that these are interrelated [ 10 , 11 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Metabolic Hormones in Schizophrenia Patients with Antipsychotic-Induced Metabolic Syndrome

Boiko

Mednova

Kornetova

et al. 2022

JPM

View full text Add to dashboard Cite

Metabolic syndrome (MetS) is a common complication of schizophrenia that is quite exacerbated by long-term use of (atypical) antipsychotics. The mechanism of MetS has neuronal, neuroendocrine, and neuroimmunological components and shows some overlap with those of aspects of schizophrenia. We examined 195 patients with schizophrenia (90 with and 105 without MetS) for the association of serum levels of ghrelin, insulin, and leptin with metabolic abnormalities. Serum glucose levels and lipid profiles were routinely measured with colorimetric enzymatic methods and hormone levels with multiplex analyzers. Leptin levels were highly significantly increased (p < 0.001) in people with MetS (9.966 [5.882; 21.496] vs. 6.35 [2.005; 11.753], Me [Q1; Q3]) and ghrelin levels were actually significantly decreased (p = 0.045). Insulin levels did not differ significantly between those with and without MetS (p = 0.162). In Spearman’s correlation analysis between the hormone levels, body characteristics, and biochemical parameters, significant correlations were seen somewhat more often in people without MetS than in those with MetS and also less often for ghrelin than for the other hormones. We conclude that evidence exists for a role in the development of MetS especially for leptin, but that less is supporting a role for ghrelin.

show abstract

Section: Discussionmentioning

confidence: 79%

Section: Introductionmentioning

confidence: 99%

Metabolic Hormones in Schizophrenia Patients with Antipsychotic-Induced Metabolic Syndrome

Boiko

Mednova

Kornetova

et al. 2022

JPM

View full text Add to dashboard Cite

show abstract

“…The small sample from Iran reported gender differences in the prevalence of MetS in rst-episode Sch patients using three different MetS diagnostic criteria (all were more higher in females) [40]. Another study with 303 Spanish FTDN Sch patients reported a signi cantly higher prevalence of high WC (a component of MetS) in females than in males [41]. In conclusion, the presence of sex differences in the prevalence of MetS may be an important clinical feature of FTDN Sch patients.…”

Section: Discussionmentioning

confidence: 81%

Gender differences in prevalence and associated factors of metabolic syndrome in first-treatment and drug-naïve schizophrenia patients

Zeng¹,

Wang²,

Zhang³

et al. 2023

Preprint

View full text Add to dashboard Cite

Background: Metabolic syndromes (MetS) are clinical syndromes involving multiple pathological states with distinct gender differences clinical patterns. As a serious psychiatric disorder, the prevalence of MetS is significantly higher in this subgroup of the population with schizophrenia (Sch). The aim of this paper is to report gender differences in the prevalence, associated factors and severity-related factors of MetS in first-treatment and drug-naïve (FTDN) Sch patients. Methods: A total of 668 patients with FTDN Sch were included in this study. Demographic and general clinical information on the included population was collected and the severity of their psychopathology was assessed. Results: In the target group, the prevalence of MetS was significantly higher in women (13.44%, 57/424) than in men (6.56%, 16/244). In the males, waist circumference (WC), fasting blood glucose (FBG), diastolic blood pressure (DBP), and triglycerides (TG) were risk factors for the diagnosis of MetS. While, systolic blood pressure (SBP), TG, total cholesterol (TC), low density lipoprotein cholesterol (LDL-C), and platelet (PLT) were risk factors for the females. More importantly, we found that age, LDL-C, Positive and Negative Symptom Scales (PANSS) scores and blood creatinine (CRE) were risk factors for higher MetS scores, while onset age and hemoglobin (HGB) were protective factors. Conclusion: There are gender differences in the prevalence of MetS in FTDN Sch patients, with a higher prevalence in women. Factors influencing MetS and its severity differ extensively between male and female patients. Targeted management strategies should be differentiated for patients of different genders in clinical practice.

show abstract

“…It is not difficult to find that the comorbidity of mental illness with metabolic disorders is prevalent. According to a large-scale clinical study, up to 60.7% of patients with first-episode drug-naïve schizophrenia have at least one of the five components of metabolic syndrome, compared with only 36.5% in the general population [25]. In other words, schizophrenia itself is a risk factor for metabolic disorders [26].…”

Section: Discussionmentioning

confidence: 99%

Relationship between efficacy and common metabolic parameters in first-treatment drug-naïve patients with early non-response schizophrenia: a retrospective study

Zhu¹,

Wu²,

Liu³

et al. 2023

Ann Gen Psychiatry

View full text Add to dashboard Cite

Background Comorbid metabolic disorders in patients with schizophrenia are very common. Patients with schizophrenia who respond to therapy early are often strongly predictive of better treatment outcomes. However, the differences in short-term metabolic markers between early responders and early non-responders in schizophrenia are unclear. Methods 143 first-treatment drug-naïve schizophrenia patients were included in this study and were given a single antipsychotic medication for 6 weeks after admission. After 2 weeks, the sample was divided into an early response group and an early non-response group based on psychopathological changes. For the study endpoints, we depicted the change curves of psychopathology in both subgroups and compared the differences between the two groups in terms of remission rates and multiple metabolic parameters. Results The early non-response had 73 cases (51.05%) in the 2nd week. In the 6th week, the remission rate was significantly higher in the early response group than in the early non-response group (30,42.86% vs. 8,10.96%); the body weight, body mass index, blood creatinine, blood uric acid, total cholesterol, triglyceride, low-density lipoprotein, fasting blood glucose, and prolactin of the enrolled samples were significantly increased, and high-density lipoprotein was significantly decreased. ANOVAs revealed a significant effect of treatment time on abdominal circumference, blood uric acid, total cholesterol, triglyceride, high-density lipoprotein, low-density lipoprotein, fasting blood glucose and prolactin, and a significant negative effect of early non-response to treatment on abdominal circumference, blood creatinine, triglyceride, fasting blood glucose. Conclusions Schizophrenia patients with early non-response had lower rates of short-term remission and more extensive and severe abnormal metabolic indicators. In clinical practice, patients with early non-response should be given a targeted management strategy, antipsychotic drugs should be switched on time, and active and effective interventions for their metabolic disorders should be given.

show abstract

Prevalence of metabolic syndrome and related factors in a large sample of antipsychotic naïve patients with first-episode psychosis: Baseline results from the PAFIP cohort

Cited by 12 publications

References 73 publications

Metabolic Hormones in Schizophrenia Patients with Antipsychotic-Induced Metabolic Syndrome

Metabolic Hormones in Schizophrenia Patients with Antipsychotic-Induced Metabolic Syndrome

Gender differences in prevalence and associated factors of metabolic syndrome in first-treatment and drug-naïve schizophrenia patients

Relationship between efficacy and common metabolic parameters in first-treatment drug-naïve patients with early non-response schizophrenia: a retrospective study

Contact Info

Product

Resources

About